These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 20176608

  • 1. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
    Fort J, Cuevas X, García F, Pérez-García R, Lladós F, Lozano J, Martín-Malo A, ANSWER study.
    Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
    [Abstract] [Full Text] [Related]

  • 2. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
    Anaya S, Rivera F, Sánchez de la Nieta MD, Carreño A, Vozmediano C, Alcaide MP, Arambarri M, Nieto J, Caparrós G, Ferreras I.
    Nefrologia; 2008 Aug; 28(2):186-92. PubMed ID: 18454709
    [Abstract] [Full Text] [Related]

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [Abstract] [Full Text] [Related]

  • 4. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B, Stenvinkel P.
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [Abstract] [Full Text] [Related]

  • 5. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K.
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [Abstract] [Full Text] [Related]

  • 6. Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients.
    Sturm G, Lamina C, Zitt E, Lhotta K, Lins F, Freistätter O, Neyer U, Kronenberg F.
    Nephrol Dial Transplant; 2010 Aug; 25(8):2715-22. PubMed ID: 20190241
    [Abstract] [Full Text] [Related]

  • 7. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
    Lawler EV, Gagnon DR, Fink J, Seliger S, Fonda J, Do TP, Gaziano JM, Bradbury BD.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
    [Abstract] [Full Text] [Related]

  • 8. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
    Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, Fukuhara S.
    Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
    [Abstract] [Full Text] [Related]

  • 9. Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels.
    Roberts TL, Foley RN, Weinhandl ED, Gilbertson DT, Collins AJ.
    Nephrol Dial Transplant; 2006 Jun; 21(6):1652-62. PubMed ID: 16449283
    [Abstract] [Full Text] [Related]

  • 10. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG.
    Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
    [Abstract] [Full Text] [Related]

  • 11. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study.
    Portolés J, López-Gómez JM, Aljama P.
    Nephrol Dial Transplant; 2007 Feb; 22(2):500-7. PubMed ID: 17023492
    [Abstract] [Full Text] [Related]

  • 12. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study.
    Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G, Grazi G, Rizza GM, Migliori M, Giusti R, Lippi A, Casani A, Barsotti G, Tetta C, RISCAVID Study Group.
    Nephrol Dial Transplant; 2011 Aug; 26(8):2641-8. PubMed ID: 21325348
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
    Rossert J, Gassmann-Mayer C, Frei D, McClellan W.
    Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
    [Abstract] [Full Text] [Related]

  • 14. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
    Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD.
    Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
    [Abstract] [Full Text] [Related]

  • 15. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
    Minutolo R, Conte G, Cianciaruso B, Bellizzi V, Camocardi A, De Paola L, De Nicola L.
    Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
    [Abstract] [Full Text] [Related]

  • 16. A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: better results for less work.
    Lines SW, Lindley EJ, Tattersall JE, Wright MJ.
    Nephrol Dial Transplant; 2012 Jun; 27(6):2425-9. PubMed ID: 22207330
    [Abstract] [Full Text] [Related]

  • 17. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K, Kairaitis L.
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [Abstract] [Full Text] [Related]

  • 18. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Kimata N, Akiba T, Pisoni RL, Albert JM, Satayathum S, Cruz JM, Akizawa T, Andreucci VE, Young EW, Port FK.
    Nephrol Dial Transplant; 2005 May; 20(5):927-35. PubMed ID: 15728270
    [Abstract] [Full Text] [Related]

  • 19. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
    Spinowitz BS, Pratt RD, Epoetin Delta 2002 Study Group.
    Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
    [Abstract] [Full Text] [Related]

  • 20. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW.
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.